Screening strategy for heart failure with preserved ejection fraction
Observes a screening approach to find heart failure early in adults.
Plain-language title generated from the registry record
Registry title: Copenhagen Heart Failure With Preserved Ejection Fraction
Key facts
- Where
- Hellerup, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 89 years old?
Source: NCT06685237, who can take part
Where in Denmark
- Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte HospitalHellerup, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tor Biering-Sørensen
- Trial code
- NCT06685237
- Record updated
- 5 March 2025
- Original description
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes mellitus and hypertension. In 2020, > 70% of patients with heart failure had preserved ejection fraction. The incidence and prevalence of HFpEF has been growing by 10% every 10 years relative to HF with reduced ejection fraction (HFrEF). In 2017, the prevalence of HFpEF varied from 1% to 14% based on available data from Europe and USA. HFpEF is associated with high morbidity and mortality, and patients with HFpEF have similarly high hospitalization rates as patients with HFrEF. Hence, HFpEF poses a substantial global health challenge. Despite its prevalence, HFpEF remains undiagnosed and underrecognized, necessitating a comprehensive approach to both identification and management.Read full original descriptionShow less
CoPenhagen Heart Failure With Preserved Ejection Fraction (CPH-HFpEF)
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes mellitus and hypertension. In 2020, > 70% of patients with heart failure had preserved ejection fraction. The incidence and prevalence of HFpEF has been growing by 10% every 10 years relative to HF with reduced ejection fraction (HFrEF). In 2017, the prevalence of HFpEF varied from 1% to 14% based on available data from Europe and USA. HFpEF is associated with high morbidity and mortality, and patients with HFpEF have similarly high hospitalization rates as patients with HFrEF. Hence, HFpEF poses a substantial global health challenge. Despite its prevalence, HFpEF remains undiagnosed and underrecognized, necessitating a comprehensive approach to both identification and management.
Ensuring successful treatment necessitates early identification of HFpEF. Consequently, a targeted screening strategy has been devised for the identification of HFpEF patients. Given the higher prevalence of heart failure (HF) in the elderly population, testing the screening strategy is imperative to customize it to the specific needs of vulnerable patients who may be more inclined to decline participation in the screening program.
Inclusion: Residence in the Capital Region of Denmark; Age ≥ 50 years; At least two risk factors for HFpEF defined as any of the following (for age ≥ 60 years, only one):; Hypertension; Diabetes mellitus; Chronic kidney disease; Atrial fibrillation; BMI > 25 kg/m2; Previous heart valve surgery; Ischemic heart disease; Obstructive sleep apnea; Furosemide 40 mg.
Exclusion: Prior solid organ transplantation; Dementia; Cancer diagnosed within the past 5 years (skin cancer not included); Lung disease defined as any of the following:; World Health Organization Group 1 pulmonary hypertension; Chronic pulmonary embolism; Lung fibrosis; Chronic obstructive pulmonary disease (COPD); Home oxygen; Age ≥ 90 years; Prevalent HF; Nursing home; Amyloidosis; Hemodialysis.